<?xml version="1.0" ?><!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st June 2018//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_180601.dtd"><PubmedArticleSet><PubmedArticle>    <MedlineCitation Status="In-Data-Review" Owner="NLM">        <PMID Version="1">30128845</PMID>        <DateRevised>            <Year>2018</Year>            <Month>08</Month>            <Day>27</Day>        </DateRevised>        <Article PubModel="Electronic">            <Journal>                <ISSN IssnType="Electronic">1534-6269</ISSN>                <JournalIssue CitedMedium="Internet">                    <Volume>20</Volume>                    <Issue>10</Issue>                    <PubDate>                        <Year>2018</Year>                        <Month>Aug</Month>                        <Day>20</Day>                    </PubDate>                </JournalIssue>                <Title>Current oncology reports</Title>                <ISOAbbreviation>Curr Oncol Rep</ISOAbbreviation>            </Journal>            <ArticleTitle>Triple-Negative Breast Cancers: Systematic Review of the Literature on Molecular and Clinical Features with a Focus on Treatment with Innovative Drugs.</ArticleTitle>            <Pagination>                <MedlinePgn>76</MedlinePgn>            </Pagination>            <ELocationID EIdType="doi" ValidYN="Y">10.1007/s11912-018-0726-6</ELocationID>            <Abstract>                <AbstractText Label="PURPOSE OF REVIEW" NlmCategory="OBJECTIVE">Triple-negative breast cancer (TNBC) accounts for 15-20% of diagnosed breast tumours, with higher incidence in young and African-American women, and it is frequently associated with BRCA germline mutations. Chemotherapy is the only well-established therapeutic option in both early- and advanced-stages of the disease. TNBC tumours relapse earlier after standard anthracycline- and/or taxane-based chemotherapy treatments, generally within 1-3 years after the diagnosis, and often develop visceral metastases, representing the subtype with a worse prognosis among all breast cancers. In the present review, we will provide an updated overview of the available results of recent clinical trials for this disease and we will describe the implications of the known molecular pathways representing novel targets for development of future therapies for TNBC patients.</AbstractText>                <AbstractText Label="RECENT FINDINGS" NlmCategory="RESULTS">Over the past decade, the advent of gene expression micro-array technology has led to the identification of different actionable targets including various genomic alterations, androgen receptor, PARP, PI3K, VEGF and other proteins of the angiogenic pathway. Thus, novel targeted drugs have been tested in clinical trials reporting promising results in specific TNBC molecular subgroups. Although cytotoxic chemotherapy remains the mainstay of treatment for TNBC patients, the identification of novel 'drugable' targets and pathways for developing personalized treatments represents a promising investigational approach in the management of the TNBC subtype.</AbstractText>            </Abstract>            <AuthorList CompleteYN="Y">                <Author ValidYN="Y">                    <LastName>Diana</LastName>                    <ForeName>Anna</ForeName>                    <Initials>A</Initials>                    <AffiliationInfo>                        <Affiliation>Division of Medical Oncology, Department of Precision Medicine, Università degli Studi della Campania Luigi Vanvitelli, II Policlinico via S. Pansini, 5, 80131, Naples, Italy. annadiana88@gmail.com.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Franzese</LastName>                    <ForeName>Elisena</ForeName>                    <Initials>E</Initials>                    <AffiliationInfo>                        <Affiliation>Division of Medical Oncology, Department of Precision Medicine, Università degli Studi della Campania Luigi Vanvitelli, II Policlinico via S. Pansini, 5, 80131, Naples, Italy.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Centonze</LastName>                    <ForeName>Sara</ForeName>                    <Initials>S</Initials>                    <AffiliationInfo>                        <Affiliation>Division of Medical Oncology, Department of Precision Medicine, Università degli Studi della Campania Luigi Vanvitelli, II Policlinico via S. Pansini, 5, 80131, Naples, Italy.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Carlino</LastName>                    <ForeName>Francesca</ForeName>                    <Initials>F</Initials>                    <AffiliationInfo>                        <Affiliation>Division of Medical Oncology, Department of Precision Medicine, Università degli Studi della Campania Luigi Vanvitelli, II Policlinico via S. Pansini, 5, 80131, Naples, Italy.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Corte</LastName>                    <ForeName>Carminia Maria Della</ForeName>                    <Initials>CMD</Initials>                    <AffiliationInfo>                        <Affiliation>Division of Medical Oncology, Department of Precision Medicine, Università degli Studi della Campania Luigi Vanvitelli, II Policlinico via S. Pansini, 5, 80131, Naples, Italy.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Ventriglia</LastName>                    <ForeName>Jole</ForeName>                    <Initials>J</Initials>                    <AffiliationInfo>                        <Affiliation>Division of Medical Oncology, Department of Precision Medicine, Università degli Studi della Campania Luigi Vanvitelli, II Policlinico via S. Pansini, 5, 80131, Naples, Italy.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Petrillo</LastName>                    <ForeName>Angelica</ForeName>                    <Initials>A</Initials>                    <AffiliationInfo>                        <Affiliation>Division of Medical Oncology, Department of Precision Medicine, Università degli Studi della Campania Luigi Vanvitelli, II Policlinico via S. Pansini, 5, 80131, Naples, Italy.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>De Vita</LastName>                    <ForeName>Ferdinando</ForeName>                    <Initials>F</Initials>                    <AffiliationInfo>                        <Affiliation>Division of Medical Oncology, Department of Precision Medicine, Università degli Studi della Campania Luigi Vanvitelli, II Policlinico via S. Pansini, 5, 80131, Naples, Italy.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Alfano</LastName>                    <ForeName>Roberto</ForeName>                    <Initials>R</Initials>                    <AffiliationInfo>                        <Affiliation>Division of Medical Oncology, Department of Precision Medicine, Università degli Studi della Campania Luigi Vanvitelli, II Policlinico via S. Pansini, 5, 80131, Naples, Italy.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Ciardiello</LastName>                    <ForeName>Fortunato</ForeName>                    <Initials>F</Initials>                    <AffiliationInfo>                        <Affiliation>Division of Medical Oncology, Department of Precision Medicine, Università degli Studi della Campania Luigi Vanvitelli, II Policlinico via S. Pansini, 5, 80131, Naples, Italy.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Orditura</LastName>                    <ForeName>Michele</ForeName>                    <Initials>M</Initials>                    <AffiliationInfo>                        <Affiliation>Division of Medical Oncology, Department of Precision Medicine, Università degli Studi della Campania Luigi Vanvitelli, II Policlinico via S. Pansini, 5, 80131, Naples, Italy.</Affiliation>                    </AffiliationInfo>                </Author>            </AuthorList>            <Language>eng</Language>            <PublicationTypeList>                <PublicationType UI="D016428">Journal Article</PublicationType>                <PublicationType UI="D016454">Review</PublicationType>            </PublicationTypeList>            <ArticleDate DateType="Electronic">                <Year>2018</Year>                <Month>08</Month>                <Day>20</Day>            </ArticleDate>        </Article>        <MedlineJournalInfo>            <Country>United States</Country>            <MedlineTA>Curr Oncol Rep</MedlineTA>            <NlmUniqueID>100888967</NlmUniqueID>            <ISSNLinking>1523-3790</ISSNLinking>        </MedlineJournalInfo>        <CommentsCorrectionsList>            <CommentsCorrections RefType="Cites">                <RefSource>Ann Oncol. 2015 Aug;26(8):1533-46</RefSource>                <PMID Version="1">25939896</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Ann Oncol. 2014 Aug;25(8):1536-43</RefSource>                <PMID Version="1">24915873</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>J Clin Invest. 2011 Jul;121(7):2750-67</RefSource>                <PMID Version="1">21633166</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Lancet Oncol. 2014 Jun;15(7):747-56</RefSource>                <PMID Version="1">24794243</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>N Engl J Med. 2010 Nov 11;363(20):1938-48</RefSource>                <PMID Version="1">21067385</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Breast Cancer Res. 2014 Aug 08;16(4):406</RefSource>                <PMID Version="1">25103565</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Br J Cancer. 2013 May 28;108(10):2172-7</RefSource>                <PMID Version="1">23558900</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Clin Cancer Res. 2010 Jan 15;16(2):681-90</RefSource>                <PMID Version="1">20068102</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>J Pathol. 2014 Jan;232(2):142-50</RefSource>                <PMID Version="1">24114677</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Endocr Relat Cancer. 2016 Apr;23(4):323-34</RefSource>                <PMID Version="1">26932782</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>J Clin Oncol. 2017 Jul 1;35(19):2141-2148</RefSource>                <PMID Version="1">28291390</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Nature. 2000 Aug 17;406(6797):747-52</RefSource>                <PMID Version="1">10963602</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Ann Oncol. 2016 May;27(5):812-8</RefSource>                <PMID Version="1">27052658</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>PLoS One. 2014 Dec 12;9(12):e115103</RefSource>                <PMID Version="1">25501357</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Cancer Chemother Pharmacol. 2008 Dec;63(1):189</RefSource>                <PMID Version="1">18317760</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Cancer Discov. 2012 Nov;2(11):1036-47</RefSource>                <PMID Version="1">22915752</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Ann Oncol. 2014 Jun;25(6):1122-7</RefSource>                <PMID Version="1">24669015</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Oncotarget. 2016 Jul 19;7(29):46482-46491</RefSource>                <PMID Version="1">27374089</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Breast Cancer Res. 2014 Nov 29;16(6):488</RefSource>                <PMID Version="1">25432519</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>PLoS One. 2014 Apr 17;9(4):e95475</RefSource>                <PMID Version="1">24743335</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Clin Cancer Res. 2013 Oct 1;19(19):5505-12</RefSource>                <PMID Version="1">23965901</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>BMC Cancer. 2016 Feb 23;16:143</RefSource>                <PMID Version="1">26908167</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Microbiol Mol Biol Rev. 2011 Mar;75(1):50-83</RefSource>                <PMID Version="1">21372320</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>N Engl J Med. 2017 Aug 10;377(6):523-533</RefSource>                <PMID Version="1">28578601</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Nat Rev Cancer. 2003 Jan;3(1):11-22</RefSource>                <PMID Version="1">12509763</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Cancer Epidemiol Biomarkers Prev. 2016 Jan;25(1):16-27</RefSource>                <PMID Version="1">26667886</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Nat Rev Cancer. 2004 Oct;4(10):814-9</RefSource>                <PMID Version="1">15510162</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Proc Natl Acad Sci U S A. 2010 Apr 20;107(16):7491-6</RefSource>                <PMID Version="1">20368419</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Lancet Oncol. 2018 Apr;19(4):497-509</RefSource>                <PMID Version="1">29501363</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Lancet Oncol. 2017 Oct;18(10):1360-1372</RefSource>                <PMID Version="1">28800861</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>J Natl Cancer Inst. 2003 Oct 1;95(19):1482-5</RefSource>                <PMID Version="1">14519755</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Breast Cancer Res. 2012 Mar 15;14(2):R48</RefSource>                <PMID Version="1">22420471</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Breast Cancer Res. 2014 Dec 23;16(6):3419</RefSource>                <PMID Version="1">25857409</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>J Clin Oncol. 2013 Mar 1;31(7):860-7</RefSource>                <PMID Version="1">23341518</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>N Engl J Med. 2016 Jul 7;375(1):23-34</RefSource>                <PMID Version="1">27406347</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Br J Cancer. 2013 Jan 15;108(1):155-62</RefSource>                <PMID Version="1">23169287</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Clin Cancer Res. 2016 Aug 1;22(15):3764-73</RefSource>                <PMID Version="1">26957554</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Cancer Immunol Res. 2014 Apr;2(4):361-70</RefSource>                <PMID Version="1">24764583</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Clin Cancer Res. 2007 Aug 1;13(15 Pt 1):4429-34</RefSource>                <PMID Version="1">17671126</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>J Clin Oncol. 2015 Mar 20;33(9):983-91</RefSource>                <PMID Version="1">25534375</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Proc Natl Acad Sci U S A. 2001 Sep 11;98(19):10869-74</RefSource>                <PMID Version="1">11553815</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Ann Oncol. 2016 Feb;27(2):249-56</RefSource>                <PMID Version="1">26598540</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Ann Oncol. 2014 Mar;25(3):611-8</RefSource>                <PMID Version="1">24401929</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Ann Oncol. 2011 Apr;22(4):870-6</RefSource>                <PMID Version="1">20937646</PMID>            </CommentsCorrections>        </CommentsCorrectionsList>        <KeywordList Owner="NOTNLM">            <Keyword MajorTopicYN="N">Review</Keyword>            <Keyword MajorTopicYN="N">Targeted therapies</Keyword>            <Keyword MajorTopicYN="N">Treatment</Keyword>            <Keyword MajorTopicYN="N">Triple-negative breast cancer</Keyword>        </KeywordList>    </MedlineCitation>    <PubmedData>        <History>            <PubMedPubDate PubStatus="entrez">                <Year>2018</Year>                <Month>8</Month>                <Day>22</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="pubmed">                <Year>2018</Year>                <Month>8</Month>                <Day>22</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="medline">                <Year>2018</Year>                <Month>8</Month>                <Day>22</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>        </History>        <PublicationStatus>epublish</PublicationStatus>        <ArticleIdList>            <ArticleId IdType="pubmed">30128845</ArticleId>            <ArticleId IdType="doi">10.1007/s11912-018-0726-6</ArticleId>            <ArticleId IdType="pii">10.1007/s11912-018-0726-6</ArticleId>        </ArticleIdList>    </PubmedData></PubmedArticle></PubmedArticleSet>